Objective-Fetal/neonatal alloimmune thrombocytopenia is a severe bleeding disorder, which can result in intracranial hemorrhage (ICH), leading to death or neurological sequelae. In whites, maternal anti-human platelet antigen-1a (HPA-1a) antibodies are responsible for the majority of cases. No predictive factors for ICH are available to guide prophylactic treatment during pregnancy. In this study, we investigated antibodies from mothers with ICH-positive fetal/ neonatal alloimmune thrombocytopenia and with ICH-negative fetal/neonatal alloimmune thrombocytopenia to identify serological and functional differences between the groups. Approach and Results-In an antigen capture assay, we observed a stronger binding of +ICH antibodies to endothelial cell (EC)-derived αvβ3. By absorption experiments, we subsequently identified anti-HPA-1a antibodies of anti-αvβ3 specificity in the +ICH but not in the −ICH cohort. Only the anti-αvβ3 subtype, but not the anti-β3 subtype, induced EC apoptosis of HPA-1a-positive ECs by caspase-3/7 activation, and mediated by reactive oxygen species. In addition, only the anti-αvβ3 subtype, but not the anti-β3 subtype, interfered with EC adhesion to vitronectin and with EC tube formation. 
F
etal/neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding disorder of the fetus and newborn in which maternal alloantibodies bind to the infant's platelets and cause their destruction during pregnancy and after birth. In whites, ≈80% of FNAIT cases are induced by antibodies against human platelet antigen 1a (HPA-1a). 1, 2 The most devastating risk of FNAIT is intracranial hemorrhage (ICH), leading to death or persistent neurological sequelae in ≈10% of the clinically symptomatic cases. 3, 4 It is currently unclear which factors determine whether ICH will occur. Modality of birth, birth weight, and the presence of other bleeding symptoms are not associated with ICH, and the association between low platelet counts and ICH is loose. 5, 6 In subsequent pregnancies of mothers immunized against HPA-1a, only sibling history, but no laboratory test, has been shown to be predictive for the risk of ICH. 7, 8 HPA-1a is formed by a single amino acid substitution (Leu 33 Pro) located on the flexible PSI (plexins, semaphorins, and integrins) domain of the integrin β3 chain. 9 On platelets, the β3 chain forms heterodimers either with αIIb or with αv, which functions as a fibrinogen or vitronectin receptor, respectively. 10 In contrast to αIIbβ3, αvβ3 is also found on endothelial cells (ECs), smooth muscle cells, and different cultured cells. 11 Several studies demonstrated that HPA-1a is constitutively expressed on endothelial αvβ3. 12, 13 It has also been shown that anti-HPA-1a antibodies can affect endothelial integrity and the spreading capability of these cells, 14 indicating that vascular damage may be involved in the pathomechanism of FNAIT. However, others have reported no effect of anti-HPA-1a antibodies on endothelial activation and integrity. 15 Recently, Yougbaré et al 16 demonstrated that anti-β3 isoantibodies produced in β3 knockout mice can induce ICH in pups by impairment of angiogenesis rather than by thrombocytopenia. The relevance of this finding for the development of ICH in humans is not clear, especially because ICH is far less frequent in humans than observed in the animal model, and a booster effect as described in mice is absent in men, that is, likelihood of ICH does not increase with the number of pregnancies in humans. 17 It seems likely that these differences are related to the fact that isoantibodies (in the murine model) and alloantibodies (in humans) are not alike. Furthermore, frequency and natural history of ICH in humans suggest that the composition of the maternal anti-HPA-1a antibody repertoire could diverge between FNAIT cases with and without ICH.
In this study, we asked the question whether a specific anti-HPA-1a antibody subtype exists in FNAIT cases with ICH, in comparison to FNAIT cases without ICH. Our results show that anti-HPA-1a antibodies in FNAIT cases with ICH bind specifically to the αvβ3 complex, trigger endothelial apoptosis via reactive oxygen species (ROS), and interfere with angiogenesis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Anti-HPA-1a Antibodies From +ICH and −ICH Cases Show Different Binding Patterns
The binding of anti-HPA-1a antibodies derived from −ICH cases (n=18; Table 1 ) and +ICH cases (n=18; Table 2 ) to αIIbβ3 and αvβ3 integrins derived from HPA-1aa platelets and ECs was investigated in an antigen capture assay. As shown in Figure 1 , no significant difference between the 2 cohorts was observed in their binding to platelet-derived αIIbβ3 (A). However, a significant difference was observed when binding to both platelet-derived αIIbβ3 and αvβ3 was analyzed (B). The differences between both cohorts became more significant when sera were tested against EC-derived αvβ3 immobilized by monoclonal antibodies against αvβ3 (C) and β3 (D). These results indicate that +ICH anti-HPA-1a might contain additional antibody specificity, most probably against αvβ3 compound epitope(s).
Anti-HPA-1a Antibodies From +ICH Cases Contain a Specific Anti-αvβ3 Subtype
To prove this hypothesis, we aimed to isolate anti-αvβ3 by absorbing +ICH sera with αIIbβ3-coated beads. For the evaluation of this approach, monoclonal antibodies against αIIbβ3, β3, and αvβ3 complexes were first absorbed with these beads and tested with Chinese hamster ovary cells expressing either αIIbβ3 or αvβ3. Absorption removed completely anti-β3 and anti-αIIbβ3 but not anti-αvβ3 ( Figure I in the onlineonly Data Supplement). Subsequently, all human sera were absorbed with αIIbβ3-coated beads, and the remaining anti-HPA-1a antibodies (absorbate) were retested by antigen capture assay (Figure 2A ). Absorbates from both cohorts became largely nonreactive with platelet-derived αIIbβ3 and αvβ3, with no differences between the cohorts (upper panel). In contrast, only sera from +ICH, but not from -ICH cases, showed significant reaction with EC-derived αvβ3, confirming our assumption that +ICH sera contain anti-HPA-1a specifically reactive with αvβ3 complex. Note that absorption reduced overall reactivity for both cohorts significantly (in comparison to Figure 1 ), indicating that relevant amounts of anti-αIIbβ3 and anti-β3, present in sera from both cohorts, were removed by absorption.
To further confirm the presence of anti-αvβ3 in the +ICH cohort, anti-HPA-1a antibodies present in absorbates and antibodies eluted from αIIbβ3-coated beads (eluates) were investigated by immunoprecipitation using biotin-labeled αIIbβ3-or αvβ3-transfected Chinese hamster ovary cells ( Figure 2B ). In the absorbates, anti-αvβ3 reactivity could be detected in +ICH but not in −ICH cohort, and this antibody specificity did not show cross reactivity with αIIbβ3 (neither anti-αIIbβ3 nor anti-β3). In contrast, cross-reactive antibodies against αvβ3 and αIIbβ3 were found in eluates from both cohorts. All 18 immunoblots were evaluated by integrity density measurement, demonstrating that the difference between the +ICH cohort and the -ICH cohort for anti-αvβ3 was significant (P=0.00042) in the absorbate but nonsignificant for αvβ3 (P=0.13) and αIIbβ3 (P=0.48) in eluates. Taken together, our results suggest that 3 different subtypes of anti-HPA-1a antibodies can exist in FNAIT sera: anti-αIIbβ3, anti-β3, and anti-αvβ3. In contrast to −ICH cases, sera from +ICH cases contain significant amounts of the anti-αvβ3 subtype.
Anti-αvβ3 Subtype of Anti-HPA1a Interferes With EC Functions
On the basis of the fact that the anti-αvβ3 subtype is present in sera from +ICH cases and reacts predominantly with ECs, we sought to investigate whether this antibody type interferes with EC function. All functional experiments were performed with IgG fractions obtained from human sera (n=9) from each cohort, both before (pre) and after (post) absorption with αIIbβ3-coated beads.
First, interference of receptor-ligand binding was analyzed by cell adhesion assay. ECs were incubated with isolated IgG fractions before adhesion onto vitronectin-coated wells. As shown in Figure 3A , +ICH IgG significantly inhibited EC adhesion (black), whereas −ICH IgG did not (white). Removal of anti-HPA-1a antibodies of the anti-β3 and anti-αIIbβ3 subtypes ( Figure 3A , post) had no influence on this effect, demonstrating that this effect was mediated by the anti-αvβ3 subtype.
It is known that disruption of EC adhesion onto extracellular matrix results in detachment-induced apoptosis, termed anoikis, which is associated with increased intracellular ROS level. 18, 19 To analyze whether antibodies of the anti-αvβ3 subtype can also trigger endothelial anoikis, the generation of intracellular ROS induced by anti-HPA-1a antibodies was first measured by oxidation of DCFDA (2',7'-dichlorodihydrofluorescein diacetate) using flow cytometry. As shown in Figure 3B , only +ICH IgG (black) induced ROS, both pre and post absorption, indicating that the anti-αvβ3 subtype triggers ROS production. In the presence of AEBSF (4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride), a specific inhibitor of nicotinamide adenine dinucleotide phosphate oxidase, 20 ROS production was abrogated. Similar results were obtained with N-acetylcysteine (data not shown).
In accordance with these observations, binding of the antiαvβ3 subtype triggered endothelial apoptosis as measured by caspase 3/7 assay ( Figure 3C ). In particular, the apoptosis rate induced by +ICH IgG remained unchanged after removal of the other subtypes (pre versus post; P=0.106). Apoptosis was confirmed by morphological assessment of chromatin DNA cleavage ( Figure 3C ).
Subsequently, an endothelial tube formation assay was performed to analyze whether the anti-αvβ3 antibody subtype would also affect angiogenesis ( Figure 3D ). +ICH IgG (black), but not −ICH IgG (white), significantly reduced tube length. Again, only the anti-αvβ3 subtype mediated the biological effect; removal of the other antibody subtypes by absorption had no influence on tube formation. The biological effect was ROS dependent and could be abrogated by AEBSF. Representative microphotographs are shown in Figure 3D (bottom). Finally, HPA-1bb ECs remained unaffected in all experiments in the presence of any of the IgG preparations (data not shown). Taken together, the anti-αvβ3 subtype bound specifically to HPA-1a expressed on ECs, inhibited cellular adhesion to vitronectin, caused cell apoptosis (anoikis), and consequently disturbed angiogenesis.
Detection of the Anti-αvβ3 Subtype as a Potential Predictive Parameter for ICH
Once anti-HPA-1a of the β3-subtype has been removed from the serum, clinically relevant anti-HPA-1a of the anti-αvβ3 subtype can be demonstrated in an antigen capture assay (Figure 2A,  bottom) . We noticed that the use of some monoclonal capture antibodies results in reduced sensitivity (Figure 2A , bottom, left), most probably caused by competitive inhibition between monoclonal and human antibodies. Adjusting the current assay (right diagram) to 100% specificity (no false-positive detection of anti-αvβ3 subtype in the −ICH cohort), 1 of 18 anti-HPA1a of the anti-αvβ3 subtype cannot be identified in the +ICH cohort, resulting in a negative predictive value of 94.7%.
Discussion
The reason how and why ICH occurs in newborns with FNAIT is still unknown. The association between platelet count and ICH is weak, and ICH has been reported in FNAIT cases where the platelet count was within the reference range. 6, 21 This indicates that biological effects of anti-HPA-1a antibodies other than increased platelet turnover may be responsible for the development of ICH. In this study, we demonstrate that maternal sera from +ICH cases, but not −ICH cases, contain significant amounts of anti-HPA-1a antibodies, which exclusively react with the αvβ3 complex. Binding of this antibody subtype to ECs hinders endothelial adhesion to vitronectin, leads to cell anoikis, and interferes with angiogenesis in an ROS-dependent manner. Our results indicate that the presence of the anti-αvβ3 subtype in maternal serum is the critical cause for the development of fetal ICH in FNAIT.
It is known that the polymorphic residue Leu33Pro residing on the PSI domain of the β3-integrin subunit controls the formation of HPA-1a epitopes. 9 However, little is known about the contribution of αIIb and αv subunits to the formation of these epitopes. Recent studies demonstrated that some anti-HPA-1a 
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Platelet-derived αIIbβ3+αvβ3 Figure 2 . Identification of an anti-human platelet antigen 1a (HPA-1a) αvβ3-specific subtype in +intracranial hemorrhage (ICH) cases after absorption of other subtypes with αIIbβ3 beads. A, Maternal anti-HPA-1a antibodies (n=18 per cohort) were preabsorbed with αIIbβ3 beads to remove HPA-1a antibodies against αIIbβ3 and β3. Afterward, the absorbate was incubated with HPA-1aa platelets (top) or endothelial cells (ECs; bottom) and monoclonal antibodies (moabs) against αIIbβ3 (a), αvβ3 (c), or β3 (b and d). After cell lysis, the trimolecular antigen-antibody complex was immobilized on microtiter wells coated with antimouse IgG. Binding of anti-HPA-1a antibodies was detected with horseradish peroxidase-labeled anti-human IgG. Statistical analysis was performed by Mann-Whitney U test. Note that after absorption, αvβ3-specific anti-HPA-1a remains detectable in the +ICH cohort only (c and d). This antibody specificity reacts more readily with αvβ3 immobilized with moab AP3 (d) than with αvβ3 immobilized with moab 23C6 (c), possibly indicating epitope interference. B, Maternal anti-HPA-1a antibodies from the +ICH (top) and −ICH (bottom) cohorts were absorbed with αIIbβ3 beads. Unbound IgG (the absorbates) and bead-bound IgG (the eluates) were incubated with biotin-labeled transfected (αvβ3 and αIIbβ3) or nontransfected (mock) Chinese hamster ovary (CHO) cells, as indicated. After washings, CHO cells were lysed, and the antigen-antibody complex was precipitated with protein-G-coupled beads and separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis under nonreducing conditions. After blotting, precipitated proteins were visualized by the use of enzyme-labeled streptavidin and a chemiluminescence system. In the -ICH cohort (bottom), all antibodies were removed by the beads as indicated by a nonreactive absorbate (left). Antibodies of anti-αIIbβ3/anti-β3 specificity could be eluted from these beads (right). Note that anti-β3 is capable to pull down αIIbβ3 and αvβ3 integrins. In contrast, in the +ICH cases (top), removal of anti-αIIbβ3/anti-β3 antibodies leaves antibodies of anti-αvβ3 specificity behind (left). The eluate is reactive with both integrins, indicating the presence of anti-β3/anti-αIIbβ3 (right). One representative gel from independent experiments (n=9) is shown. OD indicates optical density. Figure 3 . The αvβ3-specific subtype of anti-human platelet antigen 1a (HPA-1a) interferes with endothelial function. IgG was purified from maternal sera from +intracranial hemorrhage (ICH) cases (n=9; black columns) and from −ICH cases (n=9; white columns) either before (pre) or after (post) absorption with αIIbβ3 beads and then further studied. A, Cell adhesion. Endothelial cells were incubated with purified IgG (20 µg/mL) and added onto microtiter wells precoated with vitronectin. After washings, adherent cells were stained with crystal violet and measured using an ELISA reader. Statistical analysis was performed by 1-way ANOVA followed by Bonferroni post hoc test. Cyclic Arg-Gly-Asp peptide (cRGD) was used as a positive control. Note that only antibodies from +ICH cases hinder endothelial cell adhesion, with no difference between pre and postabsorption experiments. B, Reactive oxygen species (ROS) production. Endothelial cells were incubated with purified IgG (20 µg/mL) in the presence of DCFDA (2',7'-dichlorodihydrofluorescein diacetate). The production of fluorescent DCF (2',7'-dichlorofluorescein) correlates with cellular ROS production and was measured by flow cytometry. AEBSF (4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride) was used as an antioxidant in some experiments, as indicated. Statistical analysis was performed by 1-way ANOVA followed by Bonferroni post hoc test. Note that only antibodies from +ICH cases induce endothelial ROS, with no difference between pre and postabsorption experiments. C, Cell apoptosis. Purified IgG (20 µg/mL) was added to endothelial monolayers, and caspase 3/7 activity was measured by luminometry (top). Some experiments were performed in the presence of an ROS inhibitor (AEBSF). antibodies bound discretely to the β3 chain, and some recognized complex (or compound) epitopes formed by αIIb and β3. [22] [23] [24] [25] Similar to αIIbβ3, point mutation Leu33Pro together with αv subunit may create HPA-1a compound-dependent HPA-1a antigenic determinants. Our structural analysis of the PSI domain of αIIbβ3 and αvβ3 shows distinct conformational states that could in theory be differentially recognized by the immune system ( Figure II in the online-only Data Supplement). However, other mechanisms may play a role.
We found in our cohorts a new anti-HPA-1a antibody subtype that reacts with compound epitopes formed by αv and β3 subunits. Accordingly, 3 different anti-HPA-1a subtypes may exist: anti-αIIbβ3 (reactive with platelets only), anti-β3 (reactive with platelets and ECs), and anti-αvβ3 (predominantly reactive with ECs). The third subtype is produced by FNAIT mothers with fetal/neonatal ICH.
It has become evident that integrin αvβ3-mediated adhesion to extracellular matrix is essential for EC growth and survival, whereas αvβ3 antagonism can induce endothelial apoptosis during angiogenesis. 26 In fact, disruption of αvβ3 ligation with monoclonal antibodies or peptide antagonist of αvβ3 caused detachment-induced endothelial anoikis 19 via activation of caspase-3 cascade 27 and impaired thereby angiogenesis. [28] [29] [30] In line with these observations, we show in this study that only the anti-αvβ3 subtype of anti-HPA-1a (that impaired αvβ3 ligation) could induce endothelial anoikis and affect angiogenesis.
Recently, Yougbaré et al 16 demonstrated that anti-β3 antibodies induce ICH in pups by impairing angiogenesis in mouse model of FNAIT. In this model, maternal isoantibodies were developed by transfusion of β3 knockout mice with wild-type platelets, and ICH frequency was increased with subsequent immunizations. In humans, however, severity of FNAIT usually does not increase with subsequent pregnancies, 17 and a high rate of ICH reoccurrence is found in previous siblings with ICH. 7, 8 Unfortunately, analysis of different antibody subtypes was not investigated in this murine model. It is conceivable that, similar to humans, anti-αvβ3 impaired angiogenesis in these pups.
Vessel development in the brain depends on cross talk between ECs and perivascular astrocytes. 31 For this process, αv integrins play an important role through regulation of transforming growth factor-β activation and expression of transforming growth factor-β responsive genes that promote vessel differentiation and stabilization. [32] [33] [34] A critical period for ICH in FNAIT is before week 28 of gestation. 35 Of note, rapid development of premature medullary veins into showerlike numerous vessels associated with extensive angiogenesis has been observed between weeks 19 and 24 of gestation. 36 Therefore, it is feasible that antibodies against αvβ3 interfere with these critical processes to provoke ICH, especially in the brain within this period. To which extent thrombocytopenia further modifies bleeding probability and severity in the fetus requires further research.
In summary, our study provides evidence that human anti-HPA-1a of anti-αvβ3, but not of anti-β3, specificity can affect fetal vessel wall integrity, a mechanism that seems to be responsible for FNAIT-associated ICH. Our findings not only contribute to our understanding of FNAIT pathology in humans but also opens the way for new diagnostic testing and treatment strategies for immunized women in subsequent pregnancies. The absence of the anti-αvβ3 subtype could indicate a lower risk (or no risk) for ICH and might allow for modification (or cessation) of prophylactic FNAIT treatment. However, larger clinical studies are necessary to evaluate the clinical value of the proposed diagnostic test. Figure 3 Continued. Some experiments were performed in the presence of an ROS inhibitor (AEBSF) as indicated. Statistical analysis was performed by 1-way ANOVA followed by Bonferroni post hoc test. Note that only antibodies from +ICH cases reduce tube length, with no difference between pre and postabsorption experiments. Bottom, Representative microphotographs of endothelial tube formation assays as outlined. C indicates control IgG from healthy donors; MFI, mean fluorescence intensity; n.s., not significant; OD, optical density; and Thr, thrombin.
